Stromedix: Untangling fibrosis
The biology of fibrosis and fibroblasts are well understood, and there are multiple pathways and targets known to regulate fibroblast activity. Yet there are no marketed drugs for fibrosis and relatively few in development, despite the importance of fibrosis in diseases of the liver, kidney, lung and heart, and morbidity and mortality equivalent to cancer. Stromedix Inc. hopes to change that equation.
Fibrosis is a tissue-level phenomenon resulting from the excessive activity of a form